All In Biotech

Drug Trial Radar · NCT07925190

A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients

A Randomized, Open-label, Multicenter Phase III Study of Mesutoclax Combined With Azacitidine Versus Venetoclax Combined With Azacitidine in the Treatment of Treatment-naive Acute Myeloid Leukemia (AML) Who Are Elderly or Ineligible for Intensive Chemotherapy

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 318 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

318

Planned (sponsor's estimate)

Start

Nov 3, 2026

Primary completion

Dec 2029

Study completion Jun 2030

Sponsor

Sponsor type
Industry
First posted
Nov 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase III study comparing Mesutoclax + azacitidine versus venetoclax + azacitidine in newly diagnosed acute myeloid leukemia (AML) patients

Conditions

  • Acute Myeloblastic Leukemia

Interventions

  • Mesutoclax (ICP-248)Drug

    125 mg QD, orally, until disease progression or other reasons for treatment discontinuation, whichever comes first.

  • Azacitidine (AZA)Drug

    75 mg/m2, Day 1-7 or Day 1-5 and Day 8-9 of each Cycle, by injection

  • VenetoclaxDrug

    400 mg QD, orally, until disease progression or other reasons for treatment discontinuation, whichever comes first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: through the study completion, approximately up to 4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.